ABSTRACT
The anti-idiotypic antibody is widely used in the field of immunology to simulate structural features or even induce the biological activity of antigens. In this study, we obtained seven anti-idiotypic single-chain variable fragments (scFv) antibodies of Cry2Aa toxin from a phage-displayed mutant library constructed using error-prone PCR technique. A mutant designated 2-12B showed the best binding ability amongst all anti-idiotypic scFv isolates to Plutella xylostella brush border membrane vesicles (BBMVs). 2-12B and Cry2Aa toxin shared a potential receptor of polycalin in P. xylostella BBMVs. Homology modeling and molecular docking demonstrated that 2-12B and Cry2Aa toxin have seven common binding amino acid residues in polycalin. Insect bioassay results suggested that 2-12 had insecticidal efficacy against P. xylostella larvae. These results indicated that the Cry2Aa anti-idiotypic scFv antibody 2-12B partially mimicked the structure and function of Cry2Aa toxin. The anti-idiotypic scFv antibody provides the basic material for the future study of surrogate molecules or new insecticidal materials.
Subject(s)
Antibodies, Anti-Idiotypic/chemistry , Antibodies, Monoclonal/chemistry , Bacillus thuringiensis Toxins/chemistry , Endotoxins/chemistry , Hemolysin Proteins/chemistry , Immunoglobulin Variable Region/chemistry , Single-Chain Antibodies/chemistry , Animals , Antibodies, Anti-Idiotypic/genetics , Antibodies, Anti-Idiotypic/immunology , Antibodies, Anti-Idiotypic/metabolism , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Bacillus thuringiensis Toxins/immunology , Bacillus thuringiensis Toxins/metabolism , Cell Membrane/metabolism , Endotoxins/immunology , Endotoxins/metabolism , Hemolysin Proteins/immunology , Hemolysin Proteins/metabolism , Immunoglobulin Variable Region/genetics , Immunoglobulin Variable Region/immunology , Immunoglobulin Variable Region/metabolism , Molecular Docking Simulation , Moths , Mutation , Peptide Library , Protein Conformation , Single-Chain Antibodies/genetics , Single-Chain Antibodies/immunology , Single-Chain Antibodies/metabolismSubject(s)
Antibodies, Anti-Idiotypic/immunology , B7-H1 Antigen/immunology , Immunoglobulin G/immunology , Optic Neuritis/chemically induced , Sunitinib/adverse effects , Visual Acuity , Aged , Antibodies, Anti-Idiotypic/metabolism , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , B7-H1 Antigen/metabolism , Carcinoma, Renal Cell/therapy , Chemotherapy, Adjuvant/adverse effects , Female , Fluorescein Angiography/methods , Fundus Oculi , Humans , Kidney Neoplasms/therapy , Nephrectomy , Optic Neuritis/diagnosis , Optic Neuritis/immunology , Sunitinib/therapeutic useABSTRACT
Recurring mycotoxins contamination has posedaseriousthreatto food safety worldwide. Competitive immunoassays are widely used techniques for high-throughput mycotoxins detection in agricultural products and foods. However, the inevitable introduction of mycotoxin conjugates produced by chemical conjugation usually results in complicated by-products, large batch errors and threats to operators and environment. Biologically derived surrogates of mycotoxin conjugates or mycotoxin standards are renewable immunoreagents. They can serve the same function as the responding counterparts in the immunoassays. The substitute-based immunoassays exhibit satisfactory sensitivity, pose less health threats to operators and environment, and contribute to the standardization of immunoassays for mycotoxins. This review focuses on the current applications of substitute-based immunoassays, clarifies their underlying mechanisms and provides a careful comparison. Challenges and future prospects are discussed.
Subject(s)
Immunoassay/methods , Mycotoxins/analysis , Antibodies, Anti-Idiotypic/immunology , Antibodies, Anti-Idiotypic/metabolism , Antigens/analysis , Antigens/immunology , Bacteriophages/metabolism , Humans , Single-Domain Antibodies/chemistry , Single-Domain Antibodies/immunologyABSTRACT
The anti-anti-sigma factor BldG has a pleiotropic function in Streptomyces coelicolor A3(2), regulating both morphological and physiological differentiation. Together with the anti-sigma factor UshX, it participates in a partner-switching activation of the sigma factor σH, which has a dual role in the osmotic stress response and morphological differentiation in S. coelicolor A3(2). In addition to UshX, BldG also interacts with the anti-sigma factor ApgA, although no target sigma factor has yet been identified. However, neither UshX nor ApgA phosphorylates BldG. This phosphorylation is provided by the anti-sigma factor RsfA, which is specific for the late developmental sigma factor σF. However, BldG is phosphorylated in the rsfA mutant, suggesting that some other anti-sigma factors containing HATPase_c kinase domain are capable to phosphorylate BldG in vivo. Bacterial two-hybrid system (BACTH) was therefore used to investigate the interactions of all suitable anti-sigma factors of S. coelicolor A3(2) with BldG. At least 15 anti-sigma factors were found to interact with BldG. These interactions were confirmed by native PAGE. In addition to RsfA, BldG is specifically phosphorylated on the conserved phosphorylation Ser57 residue by at least seven additional anti-sigma factors. However, only one of them, SCO7328, has been shown to interact with three sigma factors, σG, σK and σM. A mutant with deleted SCO7328 gene was prepared in S. coelicolor A3(2), however, no specific function of SCO7328 in growth, differentiation or stress response could be attributed to this anti-sigma factor. These results suggest that BldG is specifically phosphorylated by several anti-sigma factors and it plays a role in the regulation of several sigma factors in S. coelicolor A3(2). This suggests a complex regulation of the stress response and differentiation in S. coelicolor A3(2) through this pleiotropic anti-sigma factor.
Subject(s)
Sigma Factor/genetics , Streptomyces coelicolor/immunology , Streptomyces coelicolor/metabolism , Amino Acid Sequence/genetics , Antibodies, Anti-Idiotypic/immunology , Antibodies, Anti-Idiotypic/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Base Sequence/genetics , Gene Expression Regulation, Bacterial/genetics , Genetic Pleiotropy/genetics , Phosphorylation/genetics , Phosphotransferases/metabolism , Promoter Regions, Genetic/genetics , Sigma Factor/immunology , Sigma Factor/metabolism , Streptomyces/genetics , Streptomyces coelicolor/genetics , Transcription, Genetic/geneticsABSTRACT
Immunoglobulin E (IgE) plays a central role in the allergic response, in which cross-linking of allergen by FcεRI-bound IgE triggers mast cell and basophil degranulation and the release of inflammatory mediators. The high-affinity interaction between IgE and FcεRI is a long-standing target for therapeutic intervention in allergic disease. Omalizumab is a clinically approved anti-IgE monoclonal antibody that binds to free IgE, also with high affinity, preventing its interaction with FcεRI. All attempts to crystallize the pre-formed complex between the omalizumab Fab and the Fc region of IgE (IgE-Fc), to understand the structural basis for its mechanism of action, surprisingly failed. Instead, the Fab alone selectively crystallized in different crystal forms, but their structures revealed intermolecular Fab/Fab interactions that were clearly strong enough to disrupt the Fab/IgE-Fc complexes. Some of these interactions were common to other Fab crystal structures. Mutations were therefore designed to disrupt two recurring packing interactions observed in the omalizumab Fab crystal structures without interfering with the ability of the omalizumab Fab to recognize IgE-Fc; this led to the successful crystallization and subsequent structure determination of the Fab/IgE-Fc complex. The mutagenesis strategy adopted to achieve this result is applicable to other intractable Fab/antigen complexes or systems in which Fabs are used as crystallization chaperones.
Subject(s)
Antibodies, Anti-Idiotypic/metabolism , Crystallization/methods , Immunoglobulin E/metabolism , Immunoglobulin Fab Fragments/metabolism , Immunoglobulin Fc Fragments/metabolism , Omalizumab/metabolism , Antibodies, Anti-Idiotypic/chemistry , Crystallography, X-Ray/methods , Humans , Immunoglobulin E/chemistry , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fc Fragments/chemistry , Omalizumab/pharmacology , Protein Structure, Secondary , Protein Structure, TertiaryABSTRACT
Objective To prepare and characterize the somatostatin (SS) anti-idiotypic antibody of yolk (SS yolk Ab2 ) on the basis of successful preparation of neutralizing SS mAb1 2E7, and then to further probe the application of SS yolk Ab2 in promoting animal growth. Methods The egg-laying hens were immunized with the neutralizing SS mAb1 2E7. The eggs containing a high titer of SS yolk Ab2 were collected and the egg yolk was separated from the egg white. The SS yolk Ab2 in yolk solution was extracted by water dilution and acidification, and was purified by precipitating with cool ethanol. The titer, concentration and specificity of SS yolk Ab2 was determined by ELISA. The Ab2ß property of SS yolk Ab2 was determined by ELISA of competitive inhibition. The effect of SS yolk Ab2 on animal growth was experimented in the mice, chickens and fish. Results The SS yolk Ab2 had a titer of 1×10-5 and a concentration of 8 mg/mL. The SS yolk Ab2 could react with the rabbit antibody against SS, but not react with the rabbit antibody against growth hormone, insulin and gastrin. The immunoreaction between the SS yolk Ab2 and rabbit antibody against SS was inhibited by SS competitively. The SS yolk Ab2 could induce the mouse to produce SS Ab3 and the SS Ab3 could react with SS, which suggest that the SS yolk Ab2 was an Ab2ß. The SS yolk Ab2 was used to immunize the mice in different doses of 0.8 µg or 3.2 µg each mouse by subcutaneous injection, and to immunize the chickens in different doses of 0.8 µg or 3.2 µg each chicken through intramuscular injection, and to immunize the Doppelfish in doses of 3.2 µg each Doppelfish by immersing fishes in 2 L of sea water containing Ab2. The control animals were immunized with the same volume of physiological saline and by the same methods. One month later, the SS yolk Ab2 vaccine could increase body weight 33.5% and 37.0% in the mice, 25.6% and 34.1% in chickens, and 24.8% in the Doppelfish compared with the corresponding controls. Conclusion The SS yolk Ab2 was prepared successfully. It had a high titer, concentration and specificity. It is an Ab2ß as a vaccine can increase body weight of animals significantly by small-dose immunization only once.
Subject(s)
Antibodies, Anti-Idiotypic , Chickens , Egg Yolk , Somatostatin , Animals , Antibodies, Anti-Idiotypic/analysis , Antibodies, Anti-Idiotypic/metabolism , Egg Yolk/chemistry , Enzyme-Linked Immunosorbent Assay , Female , Fishes , Growth/physiology , Immunization , MiceABSTRACT
Anti-α-Gal responses may exert a protective effect in falciparum malaria. However, the biological role of such antibodies is still unknown during Plasmodium vivax infections. We investigated IgG and IgM responses to α-Gal in individuals with vivax malaria. Anti-α-Gal IgG and IgM levels were higher in these patients than in controls, but no significant correlation was found between parasitaemia and anti-α-Gal response, nor between this response and ABO blood group status. This is the first study to investigate anti-α-Gal antibodies in P. vivax-infected patients; a larger survey is necessary to achieve a better understanding of host immune response during vivax malaria.
Subject(s)
Antibodies, Anti-Idiotypic/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Malaria, Vivax/blood , Plasmodium vivax/immunology , Adult , Antibodies, Anti-Idiotypic/metabolism , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Malaria, Vivax/immunology , Middle Aged , Young AdultABSTRACT
INTRODUCTION: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. METHODS: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0-T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. RESULTS: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0-T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. CONCLUSION: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
Subject(s)
Antibodies, Anti-Idiotypic/metabolism , Glycogen Storage Disease Type II/drug therapy , alpha-Glucosidases/therapeutic use , Adult , Cohort Studies , Enzyme Replacement Therapy/methods , Female , Glycogen Storage Disease Type II/metabolism , Humans , Italy , Male , Middle Aged , Severity of Illness Index , Vital Capacity , alpha-Glucosidases/adverse effects , alpha-Glucosidases/metabolismABSTRACT
BACKGROUND: General features of anti-glutamic acid decarboxylase (GAD) antibody-associated limbic encephalitis are seizures, cognitive impairment, and imaging findings at the medial temporal lobes. We report a patient affected with remarkably severe anti-GAD antibody-positive encephalitis after hematopoietic stem cell transplantation (HSCT). CASE REPORT: A 5-year-old girl received HSCT due to pineoblastoma. Thirteen months after HSCT, she showed seizure clustering and altered mental status. Her anti-GAD antibody level was high, 65,100â¯U/mL (reference rangeâ¯<â¯1.5â¯U/mL). Her disease was diagnosed as autoimmune encephalitis and she received intravenous immunoglobulin (IVIG) and methylprednisolone. After the therapy, she partially recovered. Encephalitis later relapsed, however, and she showed extremely high anti-GAD antibody, 27â¯months after HSCT. Although lesions were located in the temporal and occipital lobes by MRI at 5â¯days after the relapse, very severe whole brain encephalitis was revealed at 13â¯days after the relapse. Seizures and abnormal encephalogram were resistant to IVIG and methylprednisolone. After plasma exchange, these findings were resolved. MRI revealed diffuse cerebral atrophy, 57â¯months after the relapse. No relapse has occurred for the past 5â¯years with decreased anti-GAD antibody after starting bimonthly administration of IVIG. CONCLUSION: This may be the first case of severe and recurrent anti-GAD antibody-associated autoimmune encephalitis after HSCT with specific MRI findings. No relapse has occurred since starting maintenance IVIG.
Subject(s)
Antibodies, Anti-Idiotypic/metabolism , Encephalitis , Postoperative Complications/physiopathology , Stem Cell Transplantation/adverse effects , Autoantibodies , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/therapy , Child, Preschool , Encephalitis/blood , Encephalitis/etiology , Encephalitis/immunology , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Pineal Gland/pathology , Pinealoma/diagnostic imaging , Pinealoma/therapyABSTRACT
We present a case report of a 32-year-old woman diagnosed with opticomyelitis of Devic (OMD) and systemic lupus erythematosus (SLE). The onset of neurological symptoms was with optic neuritis. Five months later the neurological deficit progressed within a few days to lower paraplegia and upper paraparesis, retention of urine and faeces, impaired somatic and deep sensation below the level of Th1 dermatome. The results from laboratory investigations confirmed anaemic syndrome, increased urea and creatinine, hypoproteinemia and severe proteinuria. The results from CSF investigations demonstrated hyperproteinorachia with extremely high Ig fractions. Serum and CSF oligoclonal bands and positive serum Aquaporin IgG 32 times higher than the upper referent limit were found. The association with SLE was confirmed by the increased levels of total ANA and anti-ds-DNA ANA. MRT visualized the spinal cord as non-homogenously hypointense on T1 and extremely hyperintense on FLAIR sequences through its whole length up to the bulbar-pontine region. The MRT findings and the serum Aquaporin IgG confirmed the diagnosis OMD. The patient was treated with intravenous immunomodulating agents. We consider the presented case of special interest because of the comorbidity of an aggressive autoimmune systemic and an organ-specific disease of the central nervous system.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Autoimmunity , Immunoglobulin G/immunology , Lupus Erythematosus, Systemic/complications , Magnetic Resonance Imaging/methods , Neuromyelitis Optica/etiology , Adult , Antibodies, Anti-Idiotypic/metabolism , Diagnosis, Differential , Female , Humans , Immunoglobulin G/metabolism , Lupus Erythematosus, Systemic/diagnosis , Neuromyelitis Optica/diagnosisABSTRACT
Anti-α-Gal responses may exert a protective effect in falciparum malaria. However, the biological role of such antibodies is still unknown during Plasmodium vivax infections. We investigated IgG and IgM responses to α-Gal in individuals with vivax malaria. Anti-α-Gal IgG and IgM levels were higher in these patients than in controls, but no significant correlation was found between parasitaemia and anti-α-Gal response, nor between this response and ABO blood group status. This is the first study to investigate anti-α-Gal antibodies in P. vivax-infected patients; a larger survey is necessary to achieve a better understanding of host immune response during vivax malaria.
Subject(s)
Humans , Adult , Middle Aged , Young Adult , Plasmodium vivax/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Antibodies, Anti-Idiotypic/blood , Malaria, Vivax/blood , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Antibodies, Anti-Idiotypic/metabolism , Malaria, Vivax/immunology , Middle AgedABSTRACT
Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, from acutely bent to extended conformations, with allosteric communication between the distant FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.
Subject(s)
Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/metabolism , Immunoglobulin E/chemistry , Immunoglobulin E/metabolism , Receptors, IgE/metabolism , B-Lymphocytes/immunology , Crystallography, X-Ray , HEK293 Cells , Humans , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fab Fragments/metabolism , Immunoglobulin Fc Fragments/chemistry , Immunoglobulin Fc Fragments/metabolism , Mast Cells/immunology , Protein Binding , Protein ConformationABSTRACT
A novel catechol-bearing polypeptide (CtP) was synthesized and used as a component of electrochemical biosensor involving both enzymatic activity and affinity-based sensing systems. Glucose oxidase (GOx) and anti-immunoglobulin G (Anti-IgG) were selected as model biorecognition elements for the selective analysis of glucose and IgG. Step-by-step surface modifications were followed using various techniques such as cyclic voltammetry (CV) and electrochemical impedance spectrometry (EIS) as well as X-ray photoelectron spectroscopy (XPS). Additionally, contact angles were measured in order to observe surface properties. Amperometric measurements using the GOx biosensor were performed at -0.7 V by following the oxygen consumption due to the enzymatic reaction in different glucose concentrations. Affinity-based interactions via IgG sensor were monitored using the differential pulse voltammetry (DPV) technique. As the "surface design with CtP" approach employed herein is generally applicable and easily adaptable to obtain functional matrices for biomolecule immobilization, CtP-coated surfaces can be promising platforms for the fabrication of various biobased sensing systems.
Subject(s)
Biosensing Techniques/methods , Catechols/chemistry , Glucose/analysis , Immunoglobulin G/analysis , Peptides/chemistry , Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/metabolism , Glucose Oxidase/chemistry , Glucose Oxidase/metabolism , Surface PropertiesABSTRACT
Paraneoplastic movement disorders are rare, autoimmune-mediated, nonmetastatic complications of malignant neoplasms. Common paraneoplastic movement disorders include paraneoplastic chorea, dystonia, cerebellar degeneration, different types of encephalitis, opsoclonus-myoclonus syndrome, stiff person syndrome, and neuromyotonia. Syndromes usually develop before tumor diagnosis, have subacute onset, and are associated with serum or cerebrospinal fluid antibodies. Two types of antibodies can be distinguished: antibodies against nuclear and cytoplasmic neuronal antigens (anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-CV2/CRMP5, anti-Gephrin, and anti-GABATRAP) and antibodies recently identified against cell surface and synaptic proteins (anti-NMDAR, anti-LGI1, and anti-Caspr2). These two types differ from each other in a few important aspects. Antibodies against cell surface and synaptic protein disrupt cell-surface antigens. Clinical symptoms are related to the disruption of antigens and potentially can be reversed by immunotherapy. The association between these antibodies and malignancy is much less consistent. On the other hand, antibodies against nuclear and cytoplasmic neuronal antigens seem to be not pathogenic; however, they most likely indicate a T-cell-mediated immune response against neurons. Due to T-cell-mediated neuronal loss, response to immunotherapy is generally disappointing. Early recognition of all these diseases is crucial because it may lead to the disclosure of occult cancer. This review is focused on paraneoplastic movement disorders with emphasis on clinical presentations, investigational findings, and therapeutic results.
Subject(s)
Movement Disorders/etiology , Paraneoplastic Syndromes/complications , Antibodies, Anti-Idiotypic/metabolism , Humans , Movement Disorders/immunology , Paraneoplastic Syndromes/immunologySubject(s)
Antibodies, Anti-Idiotypic/immunology , Desmocollins/immunology , Pemphigus/immunology , Pemphigus/pathology , Aged, 80 and over , Antibodies, Anti-Idiotypic/metabolism , Biomarkers/blood , Biopsy, Needle , Dermoscopy/methods , Desmocollins/metabolism , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique, Direct , Humans , Immunohistochemistry , Male , Pemphigus/classification , Pemphigus/drug therapy , Prednisone/therapeutic use , Prognosis , Risk Assessment , Severity of Illness Index , Treatment OutcomeABSTRACT
INTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune disease, which has a negative impact on the ability to perform activities daily. Tumour necrosis factor α (TNF) is a cytokine with diverse cellular effects, and a key regulator of the inflammatory response. ABP 501 is a biosimilar to adalimumab, a TNF inhibitor. Areas covered: In this review, we examined ABP 501, as a biosimilar candidate to adalimumab in the treatment of RA focusing on the available data. Current data indicate that ABP 501 is a highly similar alternative to adalimumab in terms of safety, efficacy, tolerability and immunogenicity. ABP 501 has already been approved by health authorities in Europe and the United States of America, as a subcutaneous (s.c.) therapy option for the treatment of patients with RA, but also for the full spectrum approved for its bio-originator adalimumab. Expert opinion: Current body of evidence suggests that all biologic activities have been demonstrated to be equivalent between ABP 501 and the originator, including binding rates and affinity to TNF, and also the effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC). Therefore, it is fully expected to have same efficacy and safety in all indications.
Subject(s)
Arthritis, Rheumatoid/drug therapy , Biosimilar Pharmaceuticals/therapeutic use , Adalimumab/immunology , Adalimumab/pharmacokinetics , Adalimumab/therapeutic use , Antibodies, Anti-Idiotypic/metabolism , Arthritis, Rheumatoid/pathology , Biosimilar Pharmaceuticals/adverse effects , Biosimilar Pharmaceuticals/pharmacokinetics , Clinical Trials as Topic , Dose-Response Relationship, Drug , Half-Life , Humans , Tumor Necrosis Factor-alpha/immunologyABSTRACT
INTRODUCTION: Approval of the HER2-targeted antibody trastuzumab dramatically improved outcomes for patients with HER2-positive breast cancer. Multiple trastuzumab biosimilars, including ABP 980, are in clinical development. Biosimilars are not identical to the reference biologic, but exhibit equivalence and safety in analytical and clinical studies. Areas covered: A brief introduction to trastuzumab, overview of trastuzumab biosimilars, and detailed review of ABP 980 preclinical and clinical studies are included. We searched PubMed and 2016-2017 ASCO and ESMO conference proceedings for 'ABP 980' or 'trastuzumab biosimilar'. 'ABP 980 and breast cancer' or 'trastuzumab biosimilar and breast cancer' were used to search clinicaltrials.gov for phase III trials. Analytical studies of ABP 980 pharmacokinetics (PK) or pharmacodynamics (PD), phase I studies of ABP 980 safety and PK/PD, and phase III studies of clinical efficacy vs trastuzumab are included. Expert opinion: Questions remain regarding long-term impact of biosimilars on overall healthcare costs, insurance coverage of multiple approved biosimilars, and extensive clinical safety and efficacy follow-up. By producing a competitive market, trastuzumab biosimilars are anticipated to improve access to standard of care therapies, although real-world evidence remains to be obtained. Increased global access to HER2-targeted therapy may eventually alter the landscape of breast cancer and survival rates.
Subject(s)
Biosimilar Pharmaceuticals/therapeutic use , Breast Neoplasms/drug therapy , Anemia/etiology , Antibodies, Anti-Idiotypic/metabolism , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Biosimilar Pharmaceuticals/adverse effects , Biosimilar Pharmaceuticals/pharmacokinetics , Clinical Trials as Topic , Female , Humans , Receptor, ErbB-2/immunology , Receptor, ErbB-2/metabolism , Trastuzumab/adverse effects , Trastuzumab/pharmacokinetics , Trastuzumab/therapeutic useABSTRACT
Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. Here we report the crystal structure of an anti-IgE single-domain antibody in complex with an IgE Fc fragment, revealing how the antibody inhibits interactions between IgE and the two receptors FcεRI and CD23. The epitope overlaps only slightly with the FcεRI-binding site but significantly with the CD23-binding site. Solution scattering studies of the IgE Fc reveal that antibody binding induces a half-bent conformation in between the well-known bent and extended IgE Fc conformations. The antibody acts as functional homolog of CD23 and induces a closed conformation of IgE Fc incompatible with FcεRI binding. Notably the antibody displaces IgE from both CD23 and FcεRI, and abrogates allergen-mediated basophil activation and facilitated allergen binding. The inhibitory mechanism might facilitate strategies for the future development of anti-IgE therapeutics for treatment of allergic diseases.
Subject(s)
Epitopes/chemistry , Immunoglobulin E/chemistry , Receptors, IgE/chemistry , Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/metabolism , Binding Sites , Crystallography, X-Ray , Epitopes/metabolism , Humans , Immunoglobulin E/metabolism , Immunoglobulin Fc Fragments/chemistry , Immunoglobulin Fc Fragments/metabolism , Models, Molecular , Protein Binding , Protein Conformation , Receptors, IgE/metabolism , Single-Domain Antibodies/chemistry , Single-Domain Antibodies/metabolismABSTRACT
Anti-idiotypic binders which specifically recognize the variable region of monoclonal antibodies have proven to be robust tools for pharmacokinetic studies of antibody therapeutics and for the development of cancer vaccines. In the present investigation, we focused on the identification of anti-idiotypic, shark-derived IgNAR antibody variable domains (vNARs) targeting the therapeutic antibodies matuzumab and cetuximab for the purpose of developing specific capturing ligands. Using yeast surface display and semi-synthetic, CDR3-randomized libraries, we identified several highly specific binders targeting both therapeutic antibodies in their corresponding variable region, without applying any counter selections during screening. Importantly, anti-idiotypic vNAR binders were not cross-reactive towards cetuximab or matuzumab, respectively, and comprised good target recognition in the presence of human and mouse serum. When coupled to magnetic beads, anti-idiotypic vNAR variants could be used as efficient capturing tools. Moreover, a two-step procedure involving vNAR-functionalized beads was employed for the enrichment of potentially bispecific cetuximab × matuzumab antibody constructs. In conclusion, semi-synthetic and CDR3-randomized vNAR libraries in combination with yeast display enable the fast and facile identification of anti-idiotypic vNAR domains targeting monoclonal antibodies primarily in an anti-idiotypic manner.
Subject(s)
Antibodies, Anti-Idiotypic/metabolism , Antibodies, Monoclonal, Humanized/metabolism , Antineoplastic Agents, Immunological/metabolism , Cell Surface Display Techniques , Cetuximab/metabolism , Single-Domain Antibodies/metabolism , Antibodies, Anti-Idiotypic/genetics , Antibodies, Monoclonal, Humanized/isolation & purification , Antineoplastic Agents, Immunological/isolation & purification , Cetuximab/isolation & purification , Immunomagnetic Separation , Protein Binding , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Single-Domain Antibodies/geneticsABSTRACT
Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair®) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Since tools to selectively assess the efficacy of IgE BCR crosslinking by IgE targeting antibodies are limited, a readily quantifiable cell model was developed that allows to specifically address IgE BCR crosslinking activity in vitro. The new cell model allowed for a direct quantitative comparison of anti-EMPD IgE therapeutic prototype antibody 47H4 with anti-IgE(Ce3) directed therapeutic antibody Omalizumab and with a newly selected anti-human EMPD IgE monoclonal antibody, designated mAB 15cl12. Furthermore, a complementing mouse model was developed that allows for in vivo validation of antibodies addressing human EMPD IgE. It carries a targetable humanized EMPD IgE sequence that has been introduced by seamless genomic replacement of the endogenous EMPD encoding sequence. The model allowed to directly compare IgE lowering activity of two anti-human EMPD IgE therapeutic antibodies in vivo. Our tools provide the means for quantitative assessment of IgE BCR crosslinking activity which is increasingly gaining attention with respect to forthcoming second generation anti-IgE clinical candidates such as Ligelizumab or other clinical candidates featuring additional effector functions such as IgE BCR crosslinking activity.